4D pharma PLC Sponsored ADR LBPS

Market cap
$37.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '21 Jun '21 Feb '21 Dec '20 Older periods
ROE
(742.15%) (453.64%) (154.94%) (215.05%)

+8 more TTM periods

ROA
(371.23%) (337.92%) (122.50%) (103.16%)
ROIC
0.00% 0.00% (157.32%) (79.48%)
Return on Tangible Assets
(413.04%) (368.00%) (346.09%) (271.46%)
Average Days of Receivables
2,646.62 3,415.75 0.00 0.00
Free Cash Flow per Share
(0.49) (0.45) 0.00 (3.13)
Free Cash Flow
(88.99) (71.38) (55.93) (44.61)
Capital Expenditures
— (1.21) (1.67) —
Piotroski F-Score
1.00 1.00 3.00 4.00
Other line items
Cash ROIC
(135.43%) (81.83%) (104.23%) (85.69%)
Accounts Receivable Turnover
0.12 0.14 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 — 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 0.00 — 0.00
Tax Rate
(0.08) (0.09) 0.00 (0.25)
Research and Development Expense of Revenue
3,879.85% 4,822.91% — 0.00%
Selling, General and Administrative Expense of Revenue
1,414.74% 1,285.44% — 0.00%
Share Based Compensation of Revenue
0.00% 4,848.08% 0.00% —
Interest Coverage
— — 0.00 0.00
Operating CF/Net income
0.66 0.51 0.90 0.94
Depreciation/Fixed assets
0.93 0.83 1.09 1.11
Capex/Depreciation
0.00 (0.26) (0.30) 0.00
Revenue per Share
0.01 0.01 — 0.00
Operating CF per Share
(0.49) (0.44) 0.00 (3.13)
Capex per Share
0.00 (0.01) 0.00 0.00
Capex to Sales
0.00 0.94 0.00 —
Net Profit Margin
(9,577.06%) (10,604.48%) 0.00% 0.00%

Fold the line items

Columns are period end dates